Follow Merck & to never miss an important update.
A European medical committee recommended expanding the approval of Enflonsia to include children up to 24 months old who are at high risk during their second RSV season. RSV is a common respiratory virus that can lead to severe lung infections in young children. This recommendation moves the drug closer to being available for a broader group of vulnerable toddlers across Europe.
This development strengthens the company's vaccines and infectious disease portfolio. By extending protection into the second year of life, the company can reach more patients and better compete in the growing market for RSV preventatives. It is another example of the company finding new ways to generate revenue from its existing pipeline of medicines.
Source: Business Wire
The European Medicines Agency's medical committee issued a positive opinion for Welireg when used alongside another drug, lenvatinib. This combination is designed to treat adults with a specific type of advanced kidney cancer who have already tried other common therapies. While a positive opinion is not a final approval, the European Commission usually follows these recommendations within a few months.
This is a meaningful step in the company's plan to grow its oncology business beyond its top-selling drug, Keytruda. Welireg is part of a newer class of oral medicines that target how cancer cells react to low oxygen levels. Expanding its use into more treatment combinations helps the company secure a larger share of the cancer market as it prepares for older patents to expire later this decade.
Source: Business Wire
The U.S. Food and Drug Administration approved Pimjetmi for adults with tenosynovial giant cell tumors. These are non-cancerous but aggressive growths in the joints that can cause severe pain and limit movement, especially when surgery is too risky or likely to cause permanent damage.
While this drug targets a relatively small group of patients, it adds a specialized therapy to the portfolio. This helps the company continue to diversify its revenue beyond its massive cancer treatment, Keytruda, by building out its list of approved medicines for rare and difficult-to-treat conditions.
Source: Business Wire
Merck reported positive results for efinopegdutide, a drug designed to treat a liver condition called MASH where fat buildup causes inflammation and damage. In a mid-stage trial, the drug helped patients with stage 2 or 3 fibrosis, which is a level of scarring that can lead to liver failure if left untreated.
This is a key win for Merck as it tries to grow beyond its main cancer treatments. The drug works as a co-agonist, meaning it targets two different receptors in the body to manage metabolism and reduce liver fat. If future trials succeed, this could become a major product in the large and growing market for metabolic diseases.
Source: Business Wire
The FDA, which regulates medicines and food safety, granted emergency use for this treatment to address a specific parasite issue in dogs. While Merck has a large animal health business that produces vaccines and medicines for pets and livestock, this specific approval is for a niche emergency need. It is a small addition to the company's broad portfolio and does not change the overall outlook for the business.
Source: Reuters
Management consistently sets a beatable bar and clears it, with seven beats in the last eight quarters showing they have a firm handle on their complex drug pipeline.
| Expectation | |
|---|---|
| EPS | $1.78 |
| Revenue | $16.29B |